Pharma News & Analysis

Thursday, November 4, 2021

Dr. Reddy's Q2 2021 performance

 





at 12:21:00 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Newer Post Older Post Home
View mobile version

Subscribe To

Posts
Atom
Posts
Comments
Atom
Comments

Popular Posts

  • Funny Clinical Research Cartoons
  • MenAfriVac, meningitis vaccine administered to 100 millionth person
  • Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
  • Access to Medicine Index 2012
  • Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
  • Colleges offering Pharm.D in Andhra Pradesh
  • FDA agrees to review Merck's Suvorexant for sleeplessness
  • New drug approved by US FDA for the treatment of COPD
  • Computer Exercises May Offer New Hope for Alzheimer's Patients
  • IMS Health India launches total sales audit

Blog Archive

  • ►  2024 (1)
    • ►  March (1)
  • ►  2023 (16)
    • ►  November (2)
    • ►  October (7)
    • ►  May (7)
  • ►  2022 (13)
    • ►  September (8)
    • ►  July (3)
    • ►  June (1)
    • ►  April (1)
  • ▼  2021 (24)
    • ▼  November (13)
      • Eurofins Technologies Announces Launch of RT PCR k...
      • Moderna Announces Strategy to Address Omicron (B.1...
      • Dr. B Suresh resigns as PCI president
      • Enzychem to Partner with Zydus Cadila to Manufactu...
      • GE Healthcare and Optellum Collborate to Advance L...
      • GE Healthcare announces FDA Clearance for First X-...
      • Competency mapping - course in new D.Pharm syllabus
      • Competencies for the Indian D.Pharm Holders Explained
      • Competencies for the Indian D.Pharm Holders
      • Indian Pharmacopoeia Commission launches 7 New Ind...
      • Veracyte's Immunoscore Colon Cancer Test Included ...
      • Dr. Reddy's Q2 2021 performance
      • Syllabus for the post of Administrative Assistant ...
    • ►  October (8)
    • ►  September (3)
  • ►  2015 (1)
    • ►  April (1)
  • ►  2014 (4)
    • ►  January (4)
  • ►  2013 (44)
    • ►  December (20)
    • ►  November (10)
    • ►  October (2)
    • ►  September (1)
    • ►  May (3)
    • ►  April (8)
  • ►  2012 (343)
    • ►  December (2)
    • ►  November (5)
    • ►  September (112)
    • ►  August (197)
    • ►  July (5)
    • ►  April (4)
    • ►  March (10)
    • ►  February (3)
    • ►  January (5)
  • ►  2011 (121)
    • ►  December (19)
    • ►  October (9)
    • ►  September (11)
    • ►  August (30)
    • ►  June (9)
    • ►  May (8)
    • ►  April (14)
    • ►  March (11)
    • ►  February (6)
    • ►  January (4)
  • ►  2010 (105)
    • ►  December (31)
    • ►  November (10)
    • ►  August (1)
    • ►  June (7)
    • ►  April (9)
    • ►  March (4)
    • ►  February (24)
    • ►  January (19)
  • ►  2009 (222)
    • ►  December (23)
    • ►  November (6)
    • ►  October (9)
    • ►  September (16)
    • ►  August (62)
    • ►  July (32)
    • ►  June (31)
    • ►  May (17)
    • ►  March (15)
    • ►  February (11)
  • ►  2008 (29)
    • ►  December (4)
    • ►  September (1)
    • ►  July (2)
    • ►  June (6)
    • ►  May (1)
    • ►  April (5)
    • ►  March (7)
    • ►  January (3)
  • ►  2007 (3)
    • ►  December (2)
    • ►  October (1)

Topics

pharma (171) regulation (82) drugs (81) Regulatory (63) News (57) Education (55) clinical (51) clinical research (49) FDA (45) clinical trials (40) conference (29) swine flu (28) DCGI (27) Approval (25) India (25) workshop (25) markets (23) admission (19) colleges (19) company news (19) patent (19) seminar (19) job (18) research (18) vacancy (15) courses (14) IPR (11) pharm.d (11) pharmacy (11) New drugs (10) vaccines (10) IPC (9) M.Pharm (9) statistics (9) training (9) CRO (8) WHO (8) cancer (8) diseases (8) government (8) Pharmacopoeia (7) oncology (7) Awards (6) NIPER (6) Pfizer (6) expo (6) healthcare (6) people (6) sales (6) BMS (5) FDC (5) GSK (5) Industry (5) NPPA (5) PCI (5) diabetes (5) exports (5) guidance (5) spurious drugs (5) DTAB (4) DoP (4) ban (4) biotech (4) career (4) certification (4) diagnostics (4) journals (4) pharmacovigilance (4) teaching (4) CDSCO (3) Devices (3) FICCI (3) GATE (3) ICMR (3) IDMA (3) Malaria (3) Novartis (3) Roche (3) articles (3) banned drugs (3) blog (3) generics (3) interview (3) job cuts (3) law (3) market research (3) policy (3) recruitment (3) technology (3) virtual clinical trials (3) AICTE (2) AIDS (2) AIIMS (2) AstraZeneca (2) Ayush (2) BCG (2) Biocon (2) CDA (2) China (2) DLBCL (2) Deal (2) Discovery (2) EMEA (2) Europe (2) GMP (2) HIV (2) Hospital (2) IMS (2) IND (2) IPA (2) Maharastra (2) Manufacturing (2) Merck (2) Ranbaxy (2) SRF (2) Sanofi (2) Strategy (2) Weight loss (2) abstacts (2) adverticle (2) biosimilars (2) chikungunya (2) counselling (2) fraud (2) funny (2) machinery (2) manipal (2) marketing (2) meeting (2) merger (2) pharmacology (2) pricing (2) project (2) side effects (2) tamilnadu (2) testing (2) treatment (2) videos (2) ACTE (1) AIPS (1) ASBMR (1) Access to Medicine (1) Africa (1) Amylin (1) Ardea (1) Arthritis (1) Atropa (1) Awareness (1) BA/BE (1) BITS Pilani (1) British (1) CBER (1) CCMB (1) CCRH (1) CEP (1) CFDA (1) CHMP (1) CII (1) COPD (1) CPHl (1) Chronic Diseases (1) ClinicalTrials.gov (1) Colchicine (1) Crowdsourcing (1) DBT (1) DCA (1) DPCO (1) DPST (1) DST (1) Dapagliflozin (1) Diabetic retinopathy (1) Diptheria (1) Drug discontinuation (1) Drug inspector (1) Elder (1) Electroceuticals (1) Events (1) FDCA (1) FGSCDA (1) FMRAI (1) Febuxostat (1) Formulary (1) GDP (1) GOBIOM (1) GPAT (1) GVK (1) Gene (1) Gout (1) H1N1 (1) HPV (1) Heart failure (1) Hepatitis (1) ICT (1) ILDS (1) IPGA (1) IPSCON (1) IRB (1) ISCR (1) Import (1) Infants (1) Influenza (1) Innocentive (1) Insomnia (1) Internet (1) Investment (1) JOVE (1) JRF (1) JnJ (1) KDPMA (1) Launch (1) Lilly (1) MBA (1) MCI (1) MHRA (1) MedImmune (1) Media (1) Medical (1) Medical Tourism (1) Medicine (1) Medicines (1) Meningitis (1) Monographs (1) Mutation (1) NDA (1) Nanomedicine (1) Neuroscience (1) OAB (1) Obesity (1) Operations (1) Osteoarthritis (1) Ozone Pharma (1) Pharma Industry (1) Pharmexcil (1) Phase IV (1) Pipeline (1) Pneumonia (1) Preclinical (1) QA (1) QIP (1) Reference (1) SMS (1) Smoking (1) Standards (1) Sun Pharma (1) TB (1) TNCDA (1) Takeda (1) Teijin (1) Tetanus (1) Thyroid (1) Tobacco (1) UGC (1) UK (1) URL pharma (1) US (1) Wyeth (1) accredition (1) adverse effects (1) albinism (1) alternative medicine (1) amgen (1) bihar (1) bill (1) biomarker (1) biopharm (1) brain fever (1) budget (1) campaign (1) cisapride (1) contest (1) counterfeit (1) court (1) cpcsea (1) cytrx (1) degree (1) delhi (1) depression (1) device (1) diet (1) draft (1) drugs control (1) economy (1) ethics (1) exam (1) faculty (1) grants (1) hyderabad (1) info (1) informed consent (1) innovation (1) inspection (1) international (1) jobs (1) karnataka (1) kerala (1) lab (1) lesinurad (1) loans (1) misconduct (1) new year (1) nimesulide (1) novo nordisk (1) nuts (1) orchid (1) osteoporosis (1) overpricing (1) parliament (1) peanuts (1) pharmacogenomics (1) phase I (1) pictures (1) pollution (1) product safety (1) profit (1) rajasthan (1) recognition (1) report (1) resistance (1) reward (1) salary (1) scholarships (1) serum institute (1) sibutramine (1) skin cancer (1) soft tissue sarcoma (1) sri lanka (1) stiefel (1) stockists (1) support (1) survey (1) symposia (1) tanzania (1) thanks (1) transplantation (1) updates (1) virus (1) what to name it (1) youtube (1)
Copyright© 2016, Pharma News & Analysis. Powered by Blogger.